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Introduction
The term porphyria encompasses a group of dis-
eases of uncharacteristic symptomatology which all 
exhibit excessive excretion of one or more porphy-
rins, porphyrinogens and/or porphyrin precursors in 
the urine and faeces (1).
The incidence of porphyria ranges between 1: 
10 000 and 1:50 000 (1). Four exogenous factors 
- drugs, steroids, hunger and infection - can induce 
transition from the latent form of the disease into the 
acute form (3). Thus it is important for the dentist to 
know which drugs can cause an attack of porphyria, 
and those which can be applied safely.
Pathophysiology
Porphyrias are a group of diseases caused by 
defective enzymes on the biosynthetic pathway of 
heme (4).
Heme, a pigment which contains iron, is a non-
protein active ingredient of haemoproteins which 
are present in all tissues. Heme is mainly formed in 
bone marrow, where it synthesises in haemoglobin 
and in the liver, where it synthesises in cytochromes, 
of which the most important is cytochrome P-450 
which most frequently participants in drug metabo-
lism (5).
Heme biosynthesis occurs with the assistance of 
eight different enzymes which catalyse individual 
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Porphyria is a group of inherited diseases caused by defective en-
zymes on the biosynthetic pathway of heme.  Depending on the specific 
enzyme defect different forms of porphyria can be differentiated.  The 
consequence of the enzyme defect is the formation of abnormal amounts 
of porphyrins or precursors which accumulate in the tissues and are 
excreted in the urine and faeces.  Almost all the clinical signs occur be-
cause of the effect of these compounds/products on the nervous system 
and skin.  Numerous drugs, such as local anaesthetics (lidocaine), an-
tibiotics (clindamycin, erythromycin, metronidazole) and others, can be 
precipitating factors and cause acute attacks. Patients with porphyria 
can safely be given bupivacaine, amoxycillin, clavulanic acid, acethyl-
salicilic acid and paracetamol (1, 2).
Thus it is important for the dentist to have certain guidelines with 
regard to the treatment of patients with acute form of porphyria.
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steps. Depending on the specific enzyme defect dif-
ferent types of porphyria can be differentiated. In all 
porphyrias there is a raised level of synthetase del-
taaminolevulinic acid (ALA-synthetase), of the first 
enzyme on the biosynthetic pathway of heme (4). 
Heme inhibits further formation of ALA-synthetase 
(1). Certain drugs and hormones stimulate hepato-
cytes to increase the formation of ALA synthetase, 
heme and cytochromes (P-450 (3).
The consequence of the enzyme defect is the 
formation of abnormal amounts of precursor hemes 
(porphyrins) which accumulate in the tissues and are 
excreted in the urine and faeces (4). Clinical signs 
nearly always occur from the effect of these com-
pounds on the nervous system and skin.
Classification of porphyria
According to the tissue in which porphyrins 
accumulate, porphyrias can be classified as eryth-
ropoietic, in which porphyrins accumulate in bone 
marrow, and hepatic, in which porphyrins accumu-
late in the liver. The erythropoietic group includes: 
congenital erythropoietic porphyria, erythropoietic 
protoporphyria and X-linked siderblastic anaemia. 
The hepatic group includes: acute intermittent por-
phyria, cutanea tarda porphyria, hereditary cop-
roporphyria, variegate porphyria and porphyria 
defect ALA dehydratase.
A third group represents hepatoerythropoietic 
porphyrias which combine erythropoietic and hepat-
ic porphyria (1, 6).
The most frequent forms of porphyria are:
• Acute intermittent porphyria (AIP).
• Late skin porphyria.
• Hereditary coproporphyria
• Variegate porphyria (South African genetic por-
phyria) (1, 4, 6).
Acute intermittent porphyria
For the dentist the most important, and at the 
same time the most frequent acute porphyria, is 
acute intermittent porphyria (AIP).
AIP is a hepatic porphyria. The prevalence of 
AIP in the world ranges from around 1:1000-10 000, 
with greater frequency in Scandinavian countries 
and Great Britain (3, 6). It manifests after puberty 
and is most frequent in women. Drugs are usual-
ly the precipitating factor. The majority of harmful 
drugs in acute porphyria induce hepatic ALA syn-
thetase and enzyme cytochrome P-450. Other dis-
eases, surgical operations, stress, menstrual cycle 
(second half) pregnancy, psychological problems, 
alcohol have also been reported to be precipitating 
factors.
Attacks develop over several hours or days and 
last from several days to several weeks. Symp-
toms arise as a result of damage to visceral nerves. 
Most frequently they include abdominal pain, nau-
sea, vomiting, diarrhea and opstipation. The uri-
nary bladder may be involved with urine retention, 
incontinence, dysurea and polakysurea. Tachycardia 
is usual with hypertension, perspiration and restless-
ness, caused by damage to the autonomic nervous 
system or high level of catecholamines in the blood. 
Motor neuropathy often occurs. Muscular weakness 
usually starts in the shoulders and arms, although 
it can involve any neurone, including the cerebral 
nerves. Severe paralysis and respiratory insufficien-
cy may develop. Acute attacks carry a significant 
risk of death due to respiratory paralysis in 10-25% 
of patients (7).
Acute attacks require hospitalisation and infu-
sions of glucose and i.v. administration of heme, 
which suppresses synthesis of the enzyme ALA syn-
thetase by a feedback mechanism (3-5, 8, 9).
Late skin porphyria (Porphyria cutanea tarda) is 
the most frequent of all porphyrias. However, it is 
characterised only by skin symptoms, photosensi-
tivity and the occurrence of bullae. Alcohol, iron 
and estrogens are reported to be precipitating fac-
tors (6).
Hereditary coproporphyria is a hepatic porphyr-
ia. Acute attacks cannot be differentiated from those 
of AIP, and the same therapy is carried out.
Variegate porphyria is characterised by acute 
episodes of neurological and psychic disorders, with 
sensitivity of the skin to sun and also to mechanical 
stimulation. It is treated as for AIP.
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Drugs and porphyrias
When confronted with a patient suffering from 
an acute form of porphyria it is extremely impor-
tant for the dentist to be aware of the drugs which 
are known to be precipitating factors. Many lists 
have been published on drugs which are classified 
as harmful or safe for application in those suffering 
from AIP (7, 10-12). Such lists are similar in many 
ways, due to the fact that they are compiled on the 
basis of in vitro study, experimental animal studies, 
case presentations and structural similarities with 
drugs that are known to be harmful to those suf-
fering from AIP (e.g. new barbiturates or sulphon-
amides are considered harmful) (3.10). In the first 
case a false-positive result is often possible. The 
drawback of the second is the difference in physi-
ological processes of the human and animal organ-
ism, and the third case is founded on anecdotal evi-
dence (3). Thus, according to Moore, it is likely that 
all drugs which are marked as “safe” for application 
in porphyria are safe, while those which are marked 
“unsafe” are not necessarily so, but should be used 
with caution (10).
The harmlessness of local anaesthetics remains 
a controversial subject because of experimental evi-
dence of the porphyriopathy of local anaesthetics 
tested on animals (lidocaine) and cell cultures (lido-
caine, mepivacaine, bupivacaine) (10-12). For exam-
ple, Nordman et al reports that prilocaine, lidocaine, 
bupivacaine and mepivacaine are “dangerous”, and 
procaine “safe” (11). Moore reports that lidocaine 
is unsafe, and bupivacaine, procaine and prilocaine 
are safe (10). Moore and McColl report that mepi-
vacaine is unsafe, prilocaine questionable, and bupi-
vacaine and procaine safe (7). Nevertheless, clini-
cal experience has shown that these medications can 
be applied to patients with acute porphyrias with no 
noticeable side-effects.
It is recommended that bupivacaine is used for 
infiltrational and conductive anaesthesia (0.25-
0.5%) with adrenaline (1:200 000), and for topical 
lidocaine (gel 2%, spray 4-10%) (13).
Penicillin antibiotics can be used (penicillin 
G, penicillin V, amoxycillin, clavulanic acid), as 
opposed to clindamycin, erythromycin, metronida-
zole (2). However, situations have been described 
in which clindamycin was applied as a “safe drug” 
because it had previously been used in the patient 
with no negative consequence with regard to induc-
tion of AIP (5).
Of the analgesics AS acid, paracetamol and ibu-
profen can safely be applied.
Corticosteroids, which are used in the treatment 
of certain oral conditions such as lichen, recurrent 
aphthous stomatitis and pemphigus, can induce AIP 
(14).
Of other therapeutic factors the following should 
be mentioned: ethanol which is used as a vehiku-
lum in solutions for mouth rinsing, carbamazepine 
which is used in the therapy of neuralgia n. trigemi-
nus, and chlorzoxazone, a muscle relaxant of central 
effect, which can also induce AIP (2, 3).
Table 1 gives a comprehensive list of drugs 
which are of practical importance for the dentist, 
ensuring safe use in patients with acute forms of 
porphyria (2).
Conclusion
Treatment of patients with acute forms of por-
phyria represents a challenge for the dentist. With 
this in mind we give below general guidelines for 
carrying out safe and successful therapy in such 
patients.
1. While talking to the patient the dentist should ask 
about the frequency of acute episodes and when 
the last attack occurred. What factors induced 
it and whether there are prodromal symptoms 
which precede acute episodes. In what way were 
such attacks treated and was hospitalisation nec-
essary?
2. The dentist should determine the name of the 
physician treating the disease and briefly discuss 
with him/her the plan for dental therapy. It is 
necessary to decide which anaesthetic, analge-
sic, antibiotic and sedative can be included in 
the therapy and to discuss emergency therapy 
protocol in the case of an acute attack.
3. The dentist should inform the patient about 
the harmfulness of strong carbohydrate diets, 
which are prescribed for such patients, oral 
health and taking relevant contra-measures 
with regard to increased hygiene, mouth rins-
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ing with chlorzoxazone solution (which does 
not contain ethanol) and frequent check-ups 
(every 3-6 months).
4. In view of the history data the dentist should 
decide whether to refer the patient for treatment 
in an appropriate specialist institution (5).
